Combining venetoclax with azacitidine and CAG for treating refractory/relapse acute myeloid leukemia
Official title: Phase II Trial of Venetoclax in Combination With Azacitidine and CAG as Induction Therapy in Patients With Refractory/Relapse Acute Myeloid Leukemia
Run by Hematology department of the 920th hospital · NCT05807347 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new combination of medications to see if it can help people with hard-to-treat acute myeloid leukemia feel better and achieve remission.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 42 (estimated) |
| Sponsor | Hematology department of the 920th hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Kunming, Yunnan) |
| Trial ID | NCT05807347 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 65 with refractory or relapsed AML who meet specific health criteria.
✕Probably not a fit
Patients with other significant health conditions, uncontrolled infections, or those who have received prior CAG or VA regimens may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase II clinical trial evaluates the efficacy and safety of venetoclax in combination with azacitidine and CAG as an induction regimen for patients with refractory or relapsed acute myeloid leukemia (AML). The study is open-label and multicenter, aiming to enroll approximately 42 patients. Previous findings suggest that this combination therapy is well tolerated and may lead to high complete remission rates in similar patient populations. The trial will further investigate these promising results to establish a more effective treatment option for this challenging condition.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with refractory or relapsed acute myeloid leukemia.
How similar studies have gone: Previous studies have shown promising efficacy of venetoclax combined with chemotherapy in de novo AML patients, indicating potential success for this approach in refractory/relapse cases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients ≥ 18 years old and ≤ 65 years old 2. Refractory/Relapse AML patients according to 2016 World Health Organization (WHO) classification; 3. Eastern Cooperative Oncology Group (ECOG) Performance status score less than 3; 4. Liver function: Total bilirubin ≦2 upper limit of normal (ULN); aspartate aminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN 5. Renal function：Ccr（Creatinine Clearance Rate） ≧30 ml/min; Scr (serum creatinine) ≦2 ULN 6. Heart function: left ventricular ejection fraction ≧45% 7. Patients must participate in this clinical trial voluntarily and sign an informed consent form. Exclusion Criteria: 1. Other diseases； 2. AML with central nervous system (CNS) infiltration； 3. Patients have received prior CAG or VA regimen before； 4. Patients with a life expectancy \<3 months 5. Patients with uncontrolled active infection; 6. HIV infection; 7. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a) Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. b) An active second cancer that requires treatment within 6 months of study entry 8. Female who are pregnant, breast feeding or childbearing potential. 9. Patients deemed unsuitable for enrollment by the investigator;
Where it's running
-
Department of Hematology,920th Hospital of Joint Logistic Support Force of People's Liberation
Kunming, Yunnan, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Allogeneic CAR-T CT0890B for relapsed/refractory AML
This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.
-
C6 ceramide nanoliposome (CNL) treatment for relapsed or refractory acute myeloid leukemia
This will test whether C6 ceramide delivered in a nanoliposome (CNL) by IV is safe for adults whose acute myeloid leukemia has relapsed or not responded to prior treatment.
-
GI001 CAR-T for relapsed or refractory B-cell NHL and B-ALL
This treatment study tests GI001, an in vivo CAR-T therapy, to see if it is safe and helpful for adults with relapsed or refractory B-cell NHL or B-ALL.
-
Identifying risk factors for cough after lung surgery
This study is trying to find out what causes coughing after lung surgery in people with lung cancer to help improve their recovery.
-
Modified stem cell transplantation for severe aplastic anemia
This study is testing a new way of doing stem cell transplants for people with severe aplastic anemia to see if it can help them live longer and reduce complications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.